Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 217

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis

Judson, Marc A., Baughman, Robert P., Costabel, Ulrich, Drent, Marjolein, Gibson, Kevin F., Raghu, Ganesh, Shigemitsu, Hidenobu, Barney, Joseph B., Culver, Daniel A., Hamzeh, Nabeel Y., Wijsenbeek, Marlies S., Albera, Carlo, Huizar, Isham, Agarwal, Prasheen, Brodmerkel, Carrie, Watt, Rosemary, Barnathan, Elliot S.·2014·European Respiratory Journal

Abstract

Sarcoidosis is characterised by non-caseating granulomas that secrete pro-inflammatory cytokines, including interleukin (IL)-12, IL-23, and tumour necrosis factor (TNF)-α. Ustekinumab and golimumab are monoclonal antibodies that specifically inhibit IL-12/IL-23 and TNF-α, respectively. Patients with chronic pulmonary sarcoidosis (lung group) and/or skin sarcoidosis (skin group) received either 180 mg ustekinumab at week 0 followed by 90 mg every 8 weeks, 200 mg golimumab at week 0 followed by 100 mg every 4 weeks, or placebo. Patients underwent corticosteroid tapering between weeks 16 and 28. The primary end-point was week 16 change in percentage predicted forced vital capacity (ΔFVC % pred) in the lung group. Major secondary end-points were: week 28 for ΔFVC % pred, 6-min walking distance, St George's Respiratory Questionnaire (lung group), and Skin Physician Global Assessment response (skin group). At week 16, no significant differences were observed in ΔFVC % pred with ustekinumab (-0.15, p = 0.13) or golimumab (1.15, p = 0.54) compared with placebo (2.02). At week 28, there were no significant improvements in the major secondary end-points, although a nonsignificant numerically greater Skin Physician Global Assessment response was observed following golimumab treatment (53%) when compared with the placebo (30%). Serious adverse events were similar in all treatment groups. Although treatment was well tolerated, neither ustekinumab nor golimumab demonstrated efficacy in pulmonary sarcoidosis. However, trends towards improvement were observed with golimumab in some dermatological end-points.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1183/09031936.00000914

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 217

Metadata

Authors
Judson, M. A., Baughman, R. P., Costabel, U., Drent, M., Gibson, K. F., Raghu, G., Shigemitsu, H., Barney, J. B., Culver, D. A., Hamzeh, N. Y., Wijsenbeek, M. S., Albera, C., Huizar, I., Agarwal, P., Brodmerkel, C., Watt, R., & Barnathan, E. S.
Venue
European Respiratory Journal
Published
2014-07-17
Volume
44
Issue
5
Pages
1296-1307
ISSN
  • 0903-1936 (ISSN-L)
  • 1399-3003
OpenAlex
W2076158450
Cited by
217
References
1
FWCI
13.02
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. https://app.cochat.ai/papers/10.1183/09031936.00000914
The paper
Judson, M. A., Baughman, R. P., Costabel, U., Drent, M., Gibson, K. F., Raghu, G., Shigemitsu, H., Barney, J. B., Culver, D. A., Hamzeh, N. Y., Wijsenbeek, M. S., Albera, C., Huizar, I., Agarwal, P., Brodmerkel, C., Watt, R., & Barnathan, E. S. (2014). Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. European Respiratory Journal. https://doi.org/10.1183/09031936.00000914

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.